Uncategorized
Half-dose verteporfin PDT has positive outcomes in central serous chorioretinopathy
Half-dose verteporfin photodynamic therapy may be as effective as but safer than a full dose in treating patients with chronic central serous chorioretinopathy, according to a study. The retrospective study included 204 eyes of 204 patients with central serous chorioretinopathy who were treated with half-dose verteporfin PDT in a 4-year time period at Surugadai Nihon University Hospital, Tokyo.